DA-EPOCH-R Plus Ixazomib for MYC-Aberrant Lymphoid Malignancies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib for MYC-Aberrant Lymphoid Malignancies: The DACIPHOR Regimen
Blood Adv 2024 Jan 18;[EPub Ahead of Print], R Karmali, C Galvez, M Hamadani, LI Gordon, JN Winter, S Ma, V Nelson, TS Fenske, NN Shah, D Jagadeesh, AK Klein, I Helenowski, R Chen, X Mi, A Petrich, AM Evens, B ProFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.